Skip to main content

Table 1 Pooled proportions of metastatic recurrence rates in women diagnosed with breast cancer by median follow-up

From: Metastatic recurrence in women diagnosed with non-metastatic breast cancer: a systematic review and meta-analysis

 

Median follow-up time

1–4 years

5–9 years

10 + years

Total

Studies (n)

Pooled proportion (95% CI)

Studies (n)

Pooled proportion (95% CI)

Studies (n)

Pooled proportion (95% CI)

Studies (n)a

Pooled proportion (95% CI)

Overall

95

12.2 (10.5–14.0)

88

14.3 (12.9–15.7)

13

23.3 (20.1–26.8)

190

13.9 (12.8–15.1)

Source setting

 Hospital

91

12.2 (10.3–14.2)

78

15.3 (13.7–16.9)

7

23.8 (18.2–29.8)

171

14.1 (12.8–15.5)

 PBCR

5

12.2 (7–18.8)

5

8.4 (6.8–10)

5

22.7 (18.9–26.7)

15

13.6 (10.4–17.2)

 Other

0

7

10.0 (5.7–15.4)

1

7

10.0 (5.7–15.4)

Region

 Africa

5

26.4 (16.7–37.4)

1

0

6

21.7 (11.7–33.8)

 Asia

39

11.8 (9.2–14.7)

43

16.1 (13.9–18.4)

2

80

14.6 (12.6–16.7)

 Europe

17

11.0 (8.5–13.7)

31

13.2 (11.4–15)

9

21.9 (19–24.9)

55

13.8 (12.1–15.7)

 North America

29

10.2 (6.7–14.3)

10

7.7 (4.8–11.2)

2

41

10.2 (7.5–13.2)

 Oceania

2

2

0

4

17.9 (10–27.5)

 South America

3

22.6 (20.7–24.6)

1

0

4

31.5 (18.9–45.6)

Calendar year of diagnosis

 Until 1999

1

3

22.2 (15.6–29.6)

2

6

22.2 (15.1–30.3)

 From 2000 onwards

89

11.8 (9.9–13.7)

73

13.9 (12.3–15.5)

4

18.0 (14.8–21.5)

161

12.8 (11.7–14.0)

Stage at diagnosis

 Early (I–IIa)

6

4.8 (2.5–7.8)

6

6.6 (3.8–10.0)

1

13

5.9 (4.3–7.7)

 Locally advanced (IIb–IIIc)

6

33.2 (24.7–42.3)

4

35.0 (29.4–40.7)

4

35.3 (28.9–42)

13

34.5 (30.3–38.9)

Hormone receptor status

 HR+

11

9.6 (6.2–13.6)

13

10.0 (7.5–12.7)

3

13.4 (8.5–19.2)

25

9.9 (8.0–11.9)

 HR−

24

15.3 (12.1–18.8)

13

22.4 (15.8–29.7)

3

40.5 (11.4–73.7)

39

17.7 (15.0–20.7)

Age group

 < 50 years

9

16.1 (10.8–22.1)

14

19.7 (15.9–23.9)

5

20.6 (15.6–26.0)

27

18.6 (15.9–21.4)

 50–69 years

1

2

3

15.7 (12.4–19.3)

5

10.9 (9.0–12.9)

 70+ years

1

0

2

3

13.3 (9.2–18.0)

  1. aStudies do not always sum to the total due to exclusion of studies from the same city or hospital to avoid overlapping or duplicating when combining groups. Meta-analyses were performed when more than 3 studies were available